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Abstract: We determined the anticancer efficacy and internalization mechanism of our 
polymeric–ceramic nanoparticle system (calcium phosphate nanocores, enclosed in biode-
gradable polymers chitosan and alginate nanocapsules/nanocarriers [ACSC NCs]) loaded with 
iron-saturated bovine lactoferrin (Fe-bLf) in a breast cancer xenograft model. ACSC-Fe-bLf 
NCs with an overall size of 322±27.2 nm were synthesized. In vitro internalization and anti-
cancer efficacy were evaluated in the MDA-MB-231 cells using multicellular tumor spheroids, 
CyQUANT and MTT assays. These NCs were orally delivered in a breast cancer xenograft 
mice model, and their internalization, cytotoxicity, biodistribution, and anticancer efficacy were 
evaluated. Chitosan-coated calcium phosphate Fe-bLf NCs effectively (59%, P0.005) inter-
nalized in a 1-hour period using clathrin-mediated endocytosis (P0.05) and energy-mediated 
pathways (P0.05) for internalization; 3.3 mg/mL of ACSC-Fe-bLf NCs completely disinte-
grated (~130-fold reduction, P0.0005) the tumor spheroids in 72 hours and 96 hours. The 
IC
50
 values determined for ACSC-Fe-bLf NCs were 1.69 mg/mL at 10 hours and 1.62 mg/mL 
after 20 hours. We found that Fe-bLf-NCs effectively (P0.05) decreased the tumor size 
(4.8-fold) compared to the void NCs diet and prevented tumor recurrence when compared to 
intraperitoneal injection of Taxol and Doxorubicin. Receptor gene expression and micro-RNA 
analysis confirmed upregulation of low-density lipoprotein receptor and transferrin receptor 
(liver, intestine, and brain). Several micro-RNAs responsible for iron metabolism upregulated 
with NCs were identified. Taken together, orally delivered Fe-bLf NCs offer enhanced antitumor 
activity in breast cancer by internalizing via low-density lipoprotein receptor and transferrin 
receptor and regulating the micro-RNA expression. These NCs also restored the body iron and 
calcium levels and increased the hematologic counts.
Keywords: oral delivery, Fe-bLf, miRNA, xenograft, breast cancer
Introduction
Breast cancer neoplasms are the leading cause of death by cancer, among women in the world . 
More than half of the new cases of breast cancer occur in developed countries in comparison 
to the total number of incidents diagnosed worldwide.1,2 The chemotherapy offered involves 
a number of side effects during the course or after the completion of the treatment such 
as neuropathy, fatigue, leukemia, and cognitive dysfunction.3,4 Chemotherapeutics 
are also reported to impose severe problems like congestive heart failure, ventricular 
tachycardia, and sudden death.5 Alternative natural anticancer remedies have gained 
high patient compliance. It is established that milk and colostrum are a rich source of 
potential health-enhancing proteins, and bovine lactoferrin (bLf) in particular has been 
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well characterized for its antibacterial, antifungal, antiviral, 
antiparasitic, and anticancer activities.6 We have previously 
established that iron saturation increases the anticancer 
efficacy of bLf and that orally fed iron-saturated bLf (Fe-
bLf) augmented anticancer chemotherapy7 and has already 
established its anticancer activity in different cancer models.8 
Lactoferrin also replenishes the body iron content to cure 
iron deficiency and increases RBC count and hemoglobin 
levels, thereby boosting the body immune system to fight 
back against chronic diseases.8
We have also shown that calcium phosphate nanocapsules/
nanocarriers (NCs) restore the body calcium concentration, 
which is highly essential for well-being.8 Apart from this, 
most of the anticancer synthetic drugs induce drug resistance; 
however, NCs do not produce drug resistance and have a long-
term effect on treatment and prevention of cancer.9
In vivo enhancement of apoptosis and antiangiogenic 
activities creates the possibility of new objectives in order to 
carry further studies related to the intense molecular mecha-
nisms in various other cancer types, such as breast cancer. 
This is the first and novel approach as an anticancer nano-
neutraceutical for breast cancer therapy with natural protein 
that targets not only cancer cells but also cancer stem cells.9 
However, the main aim of this study was to test the antitumor 
efficacy of alginate-enclosed chitosan–calcium phosphate 
(ACSC)-Fe-bLf NCs in vitro and in vivo in xenograft breast 
cancer model. Furthermore, using immunohistochemical 
data, real-time polymerase chain reaction (RT-PCR), and 
micro-RNA (miRNA) analysis, internalization mechanism 
of the Fe-bLf–loaded NCs was evaluated in a breast cancer 
xenograft model of nude (C57BalbC nu/nu) mice.
Materials and methods
Materials
Low-molecular weight chitosan with a 20cp to 200cp 
viscosity, average molecular weight of 200 kDa and de-
acetylation degree of 80%, sodium tripolyphosphate, sodium 
alginate, potassium bromide pellets, horseradish perox-
idase–conjugated anti-goat antibody, and actin antibody 
were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia). Formvar with carbon coating on 100 mesh for 
transmission electron microscopy (TEM) analysis was from 
ProSciTech (Kirwan, QLD, Australia). TACS®MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
cell proliferation assay kit was purchased from Trevigen 
(Bio Scientific, Pty. Ltd, Kirrawee, NSW,  Australia). MDA-
MB-231 cell lines were obtained from ATCC (Manassas, 
VA, USA). Polyvinylidene fluoride membranes for  Western 
blotting were from Amersham Biosciences (Castle Hill, 
NSW, Australia). Casein-free animal diet (AIN93G rodent 
diet) was purchased from Specialty Feeds (Glen Forrest, 
WA, USA). Hematoxylin, eosin, and other immunohis-
tochemical reagents were from Lomb Scientific (Scoresby, 
VIC, Australia). Lissamine rhodamine, superscript III for 
reverse transcription was from Invitrogen Life Technolo-
gies (Mulgrave, VIC, Australia). SYBR green super mix 
for quantitative RT-PCR (qRT-PCR) was from Bio-Rad 
(Gladesville, NSW, Australia).
cell culture and conditions
Human breast cancer (MDA-MB-231) cells were grown as 
a monolayer in the Leibovitz (L-15) media supplemented 
with 10% heat-inactivated fetal bovine serum, penicillin 
(20 units/mL), and streptomycin (20 mg/mL) at 37°C in 
a saturated humid atmosphere without CO
2
. After reach-
ing 80%–90% confluency in the culture flasks, cells were 
harvested by a brief (5 min) trypsinization. For cytotoxicity 
assessment, cells were seeded onto 96-well tissue culture 
plates at concentrations of 1×103 cells/well. For RNA isola-
tion, cells were seeded onto 6- or 12-well tissue culture plates 
at a concentration of 1×106 cells/well.
saturation of blf with iron
Iron saturation of APO form (iron-free form) of bLf was 
done using Fe (III) coordinate complexes using a previously 
published methodology.7 Briefly, native bovine Lf, after treat-
ment with mild acidic solution (pH 2.6) was dialyzed for a 
period of 48 hours in 0.1 M citric acid to get rid of the bound 
metal ions and then saturated with ferric [Fe(III)] nonahydrate 
for 2 hours with stirring to form Lf-Fe3+ coordinate complexes 
for the development of deep-red-colored Fe-bLf. The resul-
tant complex was also dialyzed for a period of 48 hours to 
remove the unbound Fe. The obtained Fe-bLf was loaded 
on to the chitosan-coated calcium phosphate (CSC) NCs 
and covered with alginate (ACSC NCs) to test its size and 
effect against cancer cells.
Preparation of acsc-Fe-blf Ncs
We have reported the synthesis of alginate-enclosed chitosan-
coated ceramic NCs encapsulated with Fe-bLf in our previous 
studies.8 The same procedure was used to prepare the NCs 
in the present study. Briefly, 1% w/v calcium phosphate was 
incubated for 24 hours with 10% w/w Fe-bLf with constant 
stirring at 4°C. After adding 0.01% w/w chitosan (acetate 
buffer, pH 4), 0.01% sodium tripolyphosphate was added 
dropwise for cross-linking. Stirring at 6,000 rpm for 12 hours 
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was done to ensure that the nano-formulation obtained a 
size of 205±15 nm. Alginate solution (2% w/v) and calcium 
chloride, with 0.6% mass ratio of Ca/alginate, were added. 
The finally obtained NCs were washed and lyophilized for 
further experimentation. All the experiments were performed 
at 4°C so as to protect the polymer and protein components 
in the nano-formulation.
Determination of physical parameters 
for acsc-Fe-blf Ncs
In order to characterize the synthesized NCs, it was important 
to determine their physical parameters. Dynamic light scatter-
ing was used to determine the sizes of calcium phosphate–Fe-
bLf, calcium phosphate–chitosan–Fe-bLf (CSC-Fe-bLf), and 
alginate-encapsulated calcium phosphate–chitosan–Fe-bLf 
(ACSC-Fe-bLf) with the help of zetasizer (Malvern Zetasizer 
Nano-ZS). The number of particles per milligram per millili-
ter was also determined using the option number particle size 
index in the zetasizer. Surface morphology of these particles 
was determined by TEM (Jeol) at an accelerating voltage of 
100 kV. Samples for TEM were fixed on carbon mesh (Form-
var with carbon coating on 100 mesh) and dyed with ruthe-
nium tetroxide in order to visualize in the accelerating electric 
field at 50,000× magnification. Scanning electron microscopy 
(Supra, Zeiss) was performed to determine the shape and 
size of ACSC-Fe-bLf nanoparticles. The sample was coated 
with gold coating using SCD 050 sputter coater (Leica 
Microsystems, Wetzlar, Germany) and observed at an extra 
high tension of 10 and a working distance of 6–12 mm. The 
physicochemical characterization was performed using Fou-
rier transform infrared spectroscopy with a Bruker Vertex-70 
Fourier transform infrared spectroscope. In vitro release 
profile of the protein was carried out in varying pH (1.5, 2, 
and 8). ACSC NC (1% w/v) was suspended into phosphate 
buffered saline (PBS) at varying pH under constant stirring 
and maintained at a temperature of 37°C. The sample was 
centrifuged and dispersed in fresh solution, and the superna-
tants were analyzed for protein concentration (Bradford coo-
massie method) at various time intervals, starting from 1 hour 
till 96 hours. Calorimetric measurements were carried out 
using differential scanning calorimetry (DSC-204, Netzsch) 
with a standard crucible covered with a lid, but not sealed, in 
an atmosphere of dry nitrogen. Each sample (3–5 mg) was 
heated in an aluminum pan from 25°C to 700°C at a flow 
rate of 10°C/min under dry nitrogen. Thermogravimetric 
analysis (TGA) was also carried out to determine the thermal 
and oxidative stabilities of the NCs. The effect of varying 
the pH (2–8) was also tested on the stability and the size of 
these NCs using sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis and dynamic light scattering.
The encapsulation efficiency of the particles was deter-
mined using the following formula:10
% EE
Total protein free protein insupernatant
Total protein
= − ×100
The loading capacity of the particles was determined 
using the following formula:11
% LC
Total protein free protein in supernatant
nanoparticle
= −
 weight (mg)
×100
rhodamine labeling procedure
ACSC-Fe-bLf NCs were freeze dried and incubated in 
0.01% rhodamine (Sigma-Aldrich) solution under constant 
spinning at low speed for 24 hours. The NC suspension 
was centrifuged at 2,000 rpm for 5 minutes at 4°C. The 
supernatant was discarded, and the NC pellet was washed 
with PBS to remove the unbound rhodamine. Therefore, 
the rhodamine was not chemically linked, but adsorbed on 
the surface of the NCs as observed in previously published 
protocols.8,9
acsc Ncs uptake mechanism
In order to study the NCs uptake, MDA-MB-231 were treated 
with 1 mg/mL of 0.01% rhodamine-labeled CSC-Fe-bLf NCs 
for 1-hour, 4-hour, 6-hour, and 12-hour periods. Posttreat-
ment the cells were fixed using 4% paraformaldehyde and 
4′,6-diamidino-2-phenylindole was added, and the slides were 
viewed using Leica TCS sp5 confocal microscope. Flow cyto-
metric analysis was also performed to study the uptake mech-
anism using flow cytometric analysis in BD®FACS Canto II. 
In order to determine the mechanism of entry of NCs in cells, 
MDA-MB-231 cells were pretreated with the following endo-
cytic inhibitors: chlorpromazine 10 µg/mL (clathrin-mediated 
endocytosis), indomethacin 10 µg/mL (caveola-mediated 
endocytosis), sodium azide 2 µg/mL, and colchicine 5 µg/mL 
(pinocytosis), and antibodies to transferrin receptors (TfR) 
and low-density lipoprotein receptor (LRP) for 1 hour fol-
lowed by incubation with rhodamine-labeled ACSC-Fe-bLf 
NCs for 4 hours at a concentration of 1 mg/mL.9,12,13 Post-
treatment cell lysates were obtained, and fluorescence was 
measured at 530 nm excitation and 630 nm emission, and 
the corresponding weight of the ACSC NCs was calculated 
from the standard graph plotted for rhodamine-labeled 
ACSC NCs.
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In vitro anticancer efficacy of NCs
Agarose solution (100 µL at 0.1%) was added in 96-well 
plates. Once agar was solidified, MDA-MB-231 cells in 
a concentration of 1×103 cells per well were added. Cells 
were incubated for 7 days at 37°C with 5% CO
2
, and they 
formed uniform spheroids in all the wells.14 The spheroids 
were further treated with ACSC-Fe-bLf NCs (9.01×105) cor-
responding to 3.3 mg/mL of Fe-bLf and nano-free Fe-bLf 
protein (3.3 mg/mL) up to 96 hours. The CyQUANT cell 
proliferation assay kit was used to assess cellular proliferation 
of breast cancer cells after the treatment with NCs. Different 
formulations of NCs (void, ACSC-Fe-bLf, and CSC-Fe-
bLf) were used to treat the cells in order to observe the cell 
viability. After 20 hours incubations. Cell viability analysis 
of MDA-MB-231 cells was determined using TACS-MTT 
assay kit as per the manufacturer’s instructions. The IC
50
 
values were determined by the equation derived from respec-
tive logarithmic curves (Figures S1 and S2).
Preparation of diet containing acsc-Fe-
blf Ncs for oral therapy in vivo
The dose of Fe-bLf was standardized as in our previous studies, 
where we reported that 1.2% (w/w) or 12 g of Fe-bLf/kg 
diet prevented the tumor development.7 The same dose of 
Fe-bLf was also used in the nanoformulated diet with simi-
lar findings.8,9 The diet was checked for compatibility and 
stability of the NCs. The amount of nano-diet consumed by 
each mouse daily was also calculated.9
Induction of tumor and in vivo studies
In vivo studies were conducted in athymic nude mice 
(C57BL nu/nu, 6–8 weeks of age) subcutaneously injected with 
1×106 MDA-MB-231 (into the fat pad) cancer cells following 
the guidelines by the Animal Ethics Committee, Geelong, 
Deakin University. In preventive study, mice were fed two types 
of diet, control (no Fe-bLf NCs) diet and ACSC-Fe-bLf NC 
diet, which was further divided into two groups, where ACSC-
Fe-bLf group 1 received oral diet of ACSC-Fe-bLf NCs till the 
end of the experiment (65 days) and the diet was switched to 
normal diet upon second challenge in the case of ACSC-Fe-bLf 
group 2 (45th day). In this study, the first challenge referred 
to tumor cell injection. In the case of control group, once the 
tumor reached 200 mm3 in volume, intraperitoneal injection of 
Taxol was given. Second challenge was done on both control as 
well as treatment groups with 1×107 MDA-MB-231 cells. The 
second challenge refers to the reinjection of tumor cells, which 
was performed to mimic the situation of tumor recurrence. 
Whereas, in the case of  treatment studies, mice were fed on three 
types of diet: control diet, ACSC-Fe-bLf NCs diet, and control 
diet void NCs (without the protein). Another group of mice 
received an intraperitoneal injection of Taxol + Doxorubicin 
as a chemotherapeutic control. Body weight, behavioral 
changes, and tumor sizes were observed at regular intervals 
of 5 days each. Tumor growth was determined by measuring 
two perpendicular diameters, as described previously.15,16 In 
accordance with Animal Ethics Committee Geelong (AECG), 
animals were humanely killed once the tumors reached 1.0 cm 
in diameter. After completion of the treatment period, different 
groups of mice were sacrificed, and the tissues were harvested, 
snap frozen, and stored at -80°C until further use.
Tissue processing and hematoxylin 
and eosin staining
All the tissues were washed with PBS to remove all 
hysteresis. Intestinal sections especially were washed 
from the interior (lumen) to clear any feces. The sec-
tions were fixed using 4% paraformaldehyde, frozen 
in optimum cutting temperature compound, and stored 
at -20°C and sectioned in cryotome as 5 µm-thin sections. 
The cryotomic sections, which were placed on a glass slide, 
were fixed using ice-cold acetone solution (1:1 mixture of 
acetone and distilled water). The sections were rehydrated in 
distilled water and stained with hematoxylin and eosin using 
routine sectioning and staining techniques.
Immunohistochemistry
For immunohistochemical staining, the sections were fixed 
and rinsed in distilled water to remove the OCT compound. 
The sections were rehydrated with tris buffer saline-tween-20 
and blocked with 3% hydrogen peroxide in 0.3% rabbit 
serum to overcome endogenous peroxidase activity. Goat 
antibovine Lf antibody (Bethyl Labs, USA) (1:1,000) was 
used for the detection of exogenous Fe-bLf with anti-goat 
horseradish peroxidase–conjugated IgG secondary antibody. 
The sections were then washed in TBS-T and developed with 
DAB (3,3’-Diaminobenzidine) substrate (Sigma-Aldrich) 
and incubated for 10 minutes in dark. After counterstaining 
with hematoxylin, slides were fixed with permanent mount-
ing media and observed under 100× oil immersion objective 
using a bright-field microscope (Zeiss Axioscope 2plus).
cD31 and Prussian blue double staining
To determine angiogenic vasculature in the tissue of 
interest, 10 µm frozen sections were immunostained with 
goat anti-CD31 antibody and probed. CD31-positive 
blood vessels were detected using anti-goat IgG second-
ary antibody. Further, to develop Prussian blue staining 
and to visualize the iron reactivity, tissues were incubated 
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for 20 minutes with Prussian blue stain and the slides 
were counterstained with neutral red stain for 1 minute. 
After serial dehydration in gradients of ethanol, the slides 
were fixed with permanent mounting media and observed 
under the microscope for Prussian blue and CD31 double 
staining.
qrT-Pcr analysis
The role of LRP and TfR in translocation of Fe-bLf was 
analyzed using a previously mentioned procedure.17 RNA 
extraction was carried out by the TRizol method (Invitrogen 
Inc, USA) as per the manufacturer’s instructions, and puri-
fied RNA was confirmed by 1% agarose electrophoresis. 
Obtained RNA was converted to cDNA by SuperScript® III 
First-Strand Synthesis System (Invitrogen Inc, USA) as per 
the manufacturer’s protocol. qRT-PCR analysis of the recep-
tor genes (Table S1) was carried out by qRT-PCR system 
(Biorad Inc, USA).
regulation of mirNas involved in iron 
metabolism by alginate enclosed chitosan 
coated-calcium phosphate-Fe-blf Ncs
The cDNA was generated from 2 µg of RNA using TaqMan® 
MicroRNA Reverse Transcription Kit (Applied Biosystems) 
according to the manufacturer’s protocol. The miRNAs 
gene-specific stem-loop RT primer for reverse transcription 
was designed according to miRNAs sequences listed in the 
Sanger miRBase (http://microrna.sanger.ac.uk/sequences/) 
(Applied Biosystems).
Blood collection and analysis
Whole blood for complete blood count was collected from 
the retro-orbital plexus into EDTA-treated microtainer tubes 
(Becton Dickinson, Franklin Lakes, NJ, USA) from mice 
under Avertin (Sigma, St Louis, MO, USA) anesthesia and 
analyzed on an ADVIA 120 analyzer (Bayer, Tarrytown, 
NY). Blood smears were stained with Wright-Giemsa stain 
(Fisher Diagnostics, Middletown, VA, USA) according to 
the manufacturer’s directions. Iron, calcium, and zinc in 
the serum (Supplementary materials) were measured as 
described in our previous studies.8,9
statistical analysis
All values were expressed as mean ± standard deviation 
obtained from at least three experiments unless otherwise 
stated. For the statistical evaluation of numerical data, 
one-way analysis of variance with Duncan’s variance 
(SPSS 15) was used to compare the groups. P-values 0.05 
were considered significant.
Results and discussion
Formulation, development, and 
physicochemical characterization of Ncs
We aimed to develop a nanoformulated neutraceutical con-
trolled-release oral therapy for breast cancer. Calcium phosphate 
is known to have excellent biocompatibility,18 and chitosan 
has potential health benefits and is a mucoadhesive polymer.19 
Sodium alginate was declared generally regarded as safe for 
oral administration/consumption by the US Food and Drug 
Administration in 1973.20 Therefore, this NC has three com-
ponents: calcium phosphate–Fe-bLf nanocore, further coated 
with chitosan and Fe-bLf to form CSC NCs. The CSC NCs 
are coated with alginate to form ACSC NCs. The alginate coat-
ing is done to preserve the Fe-bLf from acidic environment in 
stomach because the un-ionized form of alginate does allow 
the protein to diffuse only in a slow rate in case of lower pH.21 
When in the intestine, the alginate layer is shed off to expose 
the final form of NCs, which is CSC NCs that are absorbed 
by the intestinal cells.8,9 On the calcium phosphate ceramic 
nanocore, 100% iron-saturated Fe-bLf was loaded followed 
by chitosan and alginate (Figure 1A).22 TEM (Figure 1B) and 
scanning electron microscopy images (Figure 1C) showed 
spherical size and particle size range of 300–350 nm. An 
average size of 205±15 nm for CSC inner core was observed, 
which was increased to 322±27.2 nm after enclosing with alg-
inate to be able to form a final ACSC-Fe-bLf NC (Figure 1D). 
The zeta potential for the NCs was found to be -1.29 mV 
due to the outer coating of alginate. A total of 4.85×104 NCs 
in 1% w/v suspension was observed during the analysis for 
the total number of NCs per milliliter of suspension. It was 
found that 0.17 mg of Fe-bLf was present in 1 mg of NCs; 
therefore, 3.57 ng of Fe-bLf was calculated to be present on 
each NC. The encapsulation efficiency of the NCs was found 
to be 80% and the loading capacity of the NCs was found 
to be 25.8% (Table 1). Controlled-release profiles of Fe-bLf 
from ACSC-Fe showed an initial burst at the end of 12 hours 
and a sustained release up to 96 hours, in a buffer in alkaline 
pH (pH 8) (Figure 1E). However, release of the protein was 
minimal in acidic pH (pH 1.5 and 2) as only 55% of the total 
protein was released by the end of 96 hours. Low release of 
the protein in the acidic pH is attributed to the pH sensitivity 
of the alginate gel.23 Alginate system maintains its structure 
without any visible changes in morphology, although Ca+2 
ions do not contribute any more to stabilize the system, 
leading to an initial burst. The un-ionized form of alginate 
does allow the protein to diffuse only in a slow rate in case 
of lower pH.21
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Figure 1 Formulation and physicochemical characterization of ceramic Ncs.
Notes: (A) The acsc-Fe-blf Ncs were found to have spherical morphology when observed under (B) transmission electron microscopy. sphericity and size of acsc-
Fe-bLf NCs were reconfirmed by (C) scanning electron microscopy. (D) Size determination using dynamic light scattering spectrometry confirmed the size of 322±27.2 nm 
for acsc-Fe-blf Ncs. (E) controlled release of Fe-blf from acsc Ncs as observed under ph 1.5, ph 2, and ph 8 in a range of time starting from 1 hour to 96 hours. 
(F) The physicochemical characterization of the Ncs was studied using Fourier transform infrared spectroscopy analysis. (G) Thermogravimetric analysis of Ncs represented 
the arrangement of different layers to protect the encapsulated protein.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; cap, calcium phosphate; csc, chitosan-coated calcium phosphate; Fe-blf, iron-saturated 
bovine lactoferrin; Ncs, nanocapsules/nanocarriers.
Table 1 comparison of physicochemical and biological characters in csc-Fe-blf Ncs and acsc-Fe-blf Ncs
Characteristics CSC-Fe-bLf NCs ACSC-Fe-bLf NCs
size, nm 205±15 322±27.2
Zeta potential, mV -0.217 -1.29
Polydispersity index 0.073 0.084
Encapsulating efficacy 80% –
loading capacity 25.8% –
Ic50 at 20 hours 1.192 mg/ml 1.62 mg/ml
Internalization efficacy (4×105 Ncs) 86.6%±2.25% 43%±1.5%
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; csc, chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; 
Ncs, nanocapsules/nanocarriers.
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Fourier transform infrared spectra of chitosan, calcium 
phosphate, CSC NCs, and ACSC NCs were obtained and 
compared (Figure 1F). Characteristic peaks of free amide and 
OH groups corresponding to chitosan were observed in both 
CSC NCs as well as in pure chitosan. Amide group vibration 
can be seen at 1,340 cm-1 in case of chitosan. The charac-
teristic peak for phosphate group in free calcium phosphate 
was observed at 924.4 cm-1 and 1,034 cm-1. A bridge peak 
corresponding to hydrogen bonding was observed in CSC 
NCs at 1,522 cm-1 proving the bonding of amino groups in 
the chitosan and phosphate group in the calcium phosphate. 
Furthermore, both phosphate and amino stretching vibrations 
were observed in ACSC NCs representing the ceramic core 
fit inside the alginate gel.
Three distinct regions of significant mass loss in the case 
of polymer-coated NCs were observed. A 10% mass loss 
was noticed between a temperature of 105°C and 247°C in 
ACSC NCs, followed by significant mass loss between the 
temperatures 265°C–330°C and 330°C–765°C, indicating the 
presence of multiple polymeric layers in the nanocomposite 
(Figure 1G). Previously published studies have reported that 
a characteristic mass loss is observed in the TGA spectra of 
calcium phosphate nanoparticles at both 200°C and 400°C 
that corresponds to loss of adsorbed water and pyrophosphate 
formation.24 The TGA analysis of chitosan–sodium tripoly-
phosphate nanoparticles was performed in another study, 
and it was reported that the maximum loss of weight occurs 
at the temperature range of 225°C–530°C.25 Meanwhile, 
studies have also reported that the maximum weight loss in 
TGA spectra of alginate is observed at 400°C.26 Therefore, 
it could be inferred that the initial mass loss at 105°C, and 
247°C corresponded to that of calcium phosphate and the sig-
nificant mass loss between the temperatures 265°C–330°C, 
330°C–765°C, and 330°C–765°C corresponded to that of 
calcium phosphate, chitosan, and alginate.
Nc stability studies and in vitro 
assessment for internalization of acsc-
Fe-blf Ncs
Differential scanning calorimetry thermograms of Fe-bLf 
protein, ACSC NCs loaded with protein, void NCs, and CSC 
NCs are shown in Figure 2A. Fe-bLf gives rise to a sharp 
peak at 272.17°C, corresponding to the melting points of 
the crystalline regions. Void NCs show a small relaxation 
peak at 87.49°C, whereas it was found at 91°C in the case 
of CSC NCs loaded with Fe-bLf. The same peak was shifted 
to 265°C in the case of ACSC NCs. Therefore, it could be 
inferred that the outer coating of chitosan and alginate had 
protective effects on the Fe-bLf. No notable melting point 
was observed in NCs as the polymers were amorphous. 
Moreover, the melting peaks of void and protein-loaded NCs 
were similar, indicating that the protein loading does not 
affect the polymer structure. In addition to this, characteristic 
peak of Fe-bLf was absent in the nanoformulation, indicating 
the conversion of crystalline protein to the amorphous form. 
The nanoparticle stability studies have been performed in 
our previous studies,9 where we have reported that the NCs 
are highly stable up to 90 weeks at 4°C–25°C. The NCs 
showed little degradation at pH 2 (Figure 2B), which was 
confirmed by dynamic light scattering. At pH 2, only 15% 
of the NCs showed degradation while 85% NCs were intact 
with the size of 300–330 nm. Therefore, this study indicated 
the stability of these NCs at acidic pH. However, at pH 8 
the size of NCs was lowered to 205 nm due to shedding of 
alginate layer (Figure 2C). These results confirm that an outer 
coating of alginate was able to protect the majority (85%) of 
NCs from acidic degradation at pH 2, which is used to mimic 
the physiological (acidic) environment within the stomach 
in mice. The key notion of using alginate layer is to protect 
the inner core from getting degraded in the gastrointestinal 
tract and alginate itself gets fragmented in the process, releas-
ing the CSC inner core. Thus, the pool of CSC NCs will be 
abundant in a total population of NCs that have reached the 
final destination.
The images obtained from confocal microscope showed 
that the rhodamine-labeled CSC NCs (4.5×105 corresponding 
to 1.6 mg/mL) successfully internalized in MDA-MB-231 cells 
within 1 hour. The nanoparticles were specifically attached to 
the cells, and there was an increase in their uptake with respect 
to time (Figure 2D). Flow cytometric analysis (Figure S3) 
showed an increase in cellular uptake of void CSC NCs 
from 21.8%±0.5% in 1 hour to 59.8%±0.9% in 12 hours, 
whereas the increase was observed to be prominent in Fe-
bLf–loaded CSC NCs from 62.5%±0.3% within 1 hour to 
85%±1.6% at 6 hours. In the case of ACSC-Fe-bLf NCs, 
the percentage of endocytosis was reduced from 1 hour to 
-6 hours; however, a slight increase by the end of 12 hours 
(23%) was observed (Figure 2E). The lower in vitro uptake 
of alginate could mainly correspond to the surface charge 
(zeta potential), which was found to be -1.29 due to the outer 
coating of alginate. Cells are also negatively charged, and 
this may be the reason as to why the ACSC NCs showed 
lower cellular uptake when compared to CSC NCs (where 
chitosan is present in the outer layer). Among all these 
inhibitors,  chlor promazine-blocked (2.4-fold) and sodium 
azide–blocked (2.4-fold) pathways led to a significant 
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Figure 2 Stability and in vitro internalization efficacy of ceramic NCs.
Notes: (A) The differential scanning calorimetry curve showed modification in the melting point and the enthalpy of melting of NCs. (B) sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis showed the stability of Nc-encapsulated Fe-blf at varying ph (2–8). (C) It was observed using dynamic light scattering that alginate layer was shed off from 
acsc-Fe-blf Ncs at alkaline ph to expose the csc-Fe-blf Ncs. (D) Confocal microscopy confirmed successful internalization of rhodamine-labeled NCs in 1 hour, which 
was found to increase with time. (E) Flow cytometric analysis shows an increase in the internalization of rhodamine-loaded csc-Fe-blf Ncs compared to void csc Ncs. 
(F) Ncs enter the cells mainly via clathrin-mediated endocytosis and energy-mediated pathways. (G) 3.3 mg/ml of Fe-blf loaded in Ncs induced a 130-fold reduction in the 
size of multicellular tumor spheroids at 72 hours and 96 hours. Data represent mean ± standard error of the mean. experiments were repeated three times independently 
with similar results. *P0.05; **P0.005; ***P0.0005.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; csc, chitosan-coated calcium phosphate; DaPI, 4′,6-diamidino-2-phenylindole; Fe-blf, iron-
saturated bovine lactoferrin; lrP, low-density lipoprotein receptor; m/w, molecular weight; Ncs, nanocapsules/nanocarriers; Tfr, transferrin receptor.
(P0.05) reduction in the uptake of NCs (Figure 2F). 
Multicellular tumor spheroids are known to mimic the in 
vivo tumor growth.27 The results from 3D tumor spheroid 
assay as observed from the graph (Figure 2G) revealed that 
MDA-MB-231 multicellular tumor spheroids treated with 
3.3 mg/mL of ACSC-Fe-bLf NCs for 96 hours showed com-
plete dissociation of the spheroids at 72 hours and 96 hours 
(represented in the wells). The tumor spheroids treated with 
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non–nano-Fe-bLf on the other hand, showed comparatively 
slower reduction rates and the tumor spheroid did not com-
pletely dissociate at 72 hours or 96 hours.
Anticancer efficacy of ACSC-Fe-bLf NCs 
in vitro
The results of MTT after 10 hours of incubation with the 
highest concentration (3.57 mg/mL) of NCs showed that 
the cell viability of cells treated with CSC-Fe-bLf (17.6%) 
was significantly low (P0.005) when compared to the cell 
viability of cells treated with ACSC-Fe-bLf (32%) and void 
(63.3%). The IC
50
 values as determined for void NCs was 
3.83 mg/mL, for ACSC-Fe-bLf it was 1.69 mg/mL, and for 
CSC-Fe-bLf it was 1.20 mg/mL (Figure 3A). The results 
from CyQUANT after 10 h showed that CSC-Fe-bLf (42.8%) 
significantly lowered (P0.005) the cell proliferation when 
compared to void NCs (92.2%) and ACSC-Fe-bLf (93%) 
(Figure 3B).
The results were reanalyzed after 20 hours of incuba-
tion, and the MTT results confirmed that cell viability 
was significantly (P0.005) lowered in CSC-Fe-bLf NCs 
(11.4%) when compared to ACSC-Fe-bLf NCs (32%) and 
void NCs (63%). The IC
50
 values for void NCs were found 
to be 4.8 mg/mL, for ACSC-Fe-bLf NCs it was 1.62 mg/mL, 
and for CSC-Fe-bLf NCs it was 1.19 mg/mL (Figure 3C). 
The cell proliferation results from CyQUANT after 20 hours 
showed that CSC-Fe-bLf (15.3%) significantly (P0.005) 
lowered the cell proliferation when compared to ACSC-
Fe-bLf NCs (63%) and void NCs (72.6%) (Figure 3D). 
The clonogenic assay results also revealed that CSC-Fe-bLf 
showed a substantial reduction in the clonogenic potential 
of MDA-MB-231 cells (Figure S4).
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Figure 3 In vitro anticancer efficacy of Fe-bLf-encapsulating ceramic NCs.
Notes: (A) The Ic50 values as determined using MTT at 10 hours for void Ncs was 3.83 mg/ml, for acsc-Fe-blf it was 1.69 mg/ml, and for csc-Fe-blf it was 1.20 mg/ml. 
(B) The results from CyQUANT after 10 hours showed that CSC-Fe-bLf (42.8%) significantly lowered (P0.005) the cell proliferation when compared to void Ncs (92.2%) 
and acsc-Fe-blf Ncs (93%). (C) The Ic50 values determined using MTT at 20 hours for void Ncs was found to be 4.8 mg/ml, for acsc-Fe-blf Ncs it was 1.62 mg/ml, and 
for csc-Fe-blf Ncs it was 1.19 mg/ml. (D) The cell proliferation results from CyQUANT after 20 hours showed that CSC-Fe-bLf (15.3%) significantly (P0.005) lowered 
the cell proliferation when compared to acsc-Fe-blf Ncs (63%) and void Ncs (72.6%). Data represent mean ± standard error of the mean. experiments were repeated 
three times independently with similar results **P0.005.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; csc, chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; 
Ncs, nanocapsules/nanocarriers.
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Determining the in vivo anticancer 
efficacy of Fe-bLf–loaded ACSC NCs
In the preventive study, mice were fed on three diet groups. 
Control or no Fe-bLf NCs diet, Fe-bLf NCs diet for 65 days 
(group 1), and Fe-bLf NCs diet only till the 45th day (group 2). 
Approximately 3.38×109 NCs containing 12 g Fe-bLf/kg diet 
were administered orally in the mice. The tumor appeared in 
mice after 10 days of injection, and once the tumor reached 
a diameter of ~45.6 mm3, it was regressed by injecting Taxol 
in control mice group. Reinjection of 1×106 MDA-MB-231 
cancer cells on the 45th day was performed to mimic the 
situation of tumor recurrence. The control group (previously 
injected with Taxol) showed development of tumor. This 
clearly showed that Taxol did not have continuous protective 
effects on the mice. On the other hand, mice fed with Fe-bLf 
NCs (both diet 1 and 2) did not show any sign of tumor growth 
in either the first challenge or the second challenge.
In our previously published studies,9 we have reported 
that during the preventive studies mice fed with Fe-bLf 
NCs did not develop tumor at all. A similar observation was 
made in the present study, where the mice fed with Fe-bLf 
NCs when injected with breast cancer cells did not develop 
tumor. Previously, we have shown that Fe-bLf NCs inhibited 
the cellular expression of survivin and its splice variants; 
downregulated key cancer stem cell markers such as CD133, 
CD44, CD166, and EpCAM; and also prevented angiogen-
esis and neo-angiogenesis. These reasons may account for 
the absence of tumor development in the preventive study.
As shown in Figure 4B, there was no effect on the body 
weight in controls group that had developed tumors and so 
is the case with the treatment groups. In fact, the average 
body weight of the treatment groups was more in comparison 
to controls and the mice remained healthy because Fe-bLf 
is a natural defense protein with anticancer properties.19,28 
body conditional score of 0–4 have indicated that the ani-
mals were healthy without any of the side effects posed by 
nanocarrier-based therapy.
In the treatment studies, it was observed that the tumor size 
increased irreversibly in mice fed on control diet (2.25-fold) and 
on void NCs diet (2.05-fold). The mice fed on ACSC-Fe-bLf 
NCs diet showed a radical decrease (3-fold) in the tumor size 
on the 65th day, which kept on decreasing until the 80th day 
(10-fold) and finally there was no tumor in the mice on 85th 
day. On the other hand, mice injected with the combination of 
Taxol and Doxorubicin, although did show an initial decrease 
from 55th to 65th day (3-fold), the tumor size was found to 
increase again on the 65th day until the 85th day (3.4-fold) 
(Figure 4C). These results clearly showed that Taxol did not 
have a continuous protective effect on the mice. Since the 
increase in tumor size was only found after 15 days of injection, 
it is possible that both the drugs would have been removed from 
the mice body.29,30 Both Taxol and Doxorubicin are also com-
monly known to induce drug resistance in breast cancer.31,32
assessment of in vivo biodistribution 
and internalization mechanism
Organs involved in NCs internalization including intestine 
(Figure 5A-a,b), brain (Figure 5A-c,d), and key components 
in reticulo-endothelial system; kidneys (Figure 5A-e,f) showed 
no abnormality. The anatomy of controlled versus treated sec-
tions retained their integrity and tissue pathology, showing a 
minimal damage to these organs with the treatment (Figure 
5A). In addition to tissue pathology, biodistribution of ACSC 
NCs was done based on the Fe-bLf functionalized on the NCs. 
In the case of treatment groups (Figure 5B), a characteristic 
immunoreactivity (brown color due to immunoreactivity) of 
Fe-bLf was seen. As represented, in the case of brain tissues, a 
mild immunoreactivity of Fe-bLf was observed (Figure 5B-b). 
Liver showed mild immunoreactivity (Figure 5B-c) as a 
function of biodegradability of the NCs. Furthermore, ileum 
(Figure 5B-f) showed intense Fe-bLf immunoreactivity cor-
responding to the proposed transcytosis of the NCs.
A significant increase in iron levels (P0.05) in the case 
of the reticulo-endothelial organs, liver (1.3±0.1 mg/ml) and 
spleen (1.7±0.1 mg/ml), was observed. Similarly, increased 
intestinal (1.5±0.03-fold) iron concentration was noticed that 
corresponds to the transcytosis. In case of brain tissues the 
iron concentration was found to be (1.4±0.1-fold) compared 
to control. Most importantly, there was a 5.33-fold increase in 
iron levels in tumor, which was highly significant (P0.005) 
when compared to the untreated control (Figure 6A). Further-
more, based on the fact that anticancer Fe-bLf was positive for 
Prussian blue staining, co-localization of NCs along with blood 
vessels was further investigated. A substantial amount of Fe-
bLf–loaded NCs was still clearly observed around the vascular 
region of the brain tissue slices (Figure 6B and C) using Prussian 
blue and CD31 double staining. At high magnification (100×), 
NCs were observed to be located in intracellular regions.
gene and mirNa analysis for the 
expression of various receptors and 
mirNa responsible for nanocapsule uptake
The results showed that in the intestine, miR196 (1.175-
fold), miR200b (1.175-fold), and miR485 (1.3-fold) showed 
effective upregulation, whereas all others were downregu-
lated. In the liver, only miR210 (1.35-fold) and miR584 
(1.175-fold) were found to be upregulated, whereas miR485 
did not show any change in expression and all others were 
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Figure 4 In vivo antitumor efficacy of ceramic NCs.
Notes: (A) Within 1 week after the injection of 107 cancer cells, tumors (~45.6 mm3) were developed in control diet–fed mice and were terminated by injecting Taxol (IP) 
when challenged for the second time, ~100.3 mm3 tumors were observed in 4 weeks. In neither of the cases (first challenge or the second challenge), significant tumors 
were developed in the treatment groups of mice. (B) average body weight of the control group remained at 14.41 g, whereas treatment groups showed an increase in body 
weight up to 17.32 g. (C) ascs-Fe-blf Nc diet showed 10-fold reduction in tumor volume from 55th day to 80th day, and on 85th day, the tumor was completely absent. 
Data represent mean ± standard error of the mean (n=5). *P0.05.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; Dox, doxorubicin; Fe-blf, iron-saturated bovine lactoferrin; IP, intraperitoneal; Ncs, 
nanocapsules/nanocarriers.
downregulated. In the spleen, miR122 (1.1-fold) was slightly 
upregulated, miR196 (1.43-fold) and miR485 (1.375-fold) 
were highly upregulated, and miR200b and miR320 did not 
show any change, whereas others were downregulated. In the 
brain, miR122 (1.18-fold), miR214 (1.23-fold), and miR485 
(1.25-fold) were found to be upregulated, whereas all others 
were found to be downregulated (Figure 6D). Lactoferrin was 
shown to be an LRP as well as a TfR ligand.33,34 Taking into 
consideration the fact that lactoferrin and transferrin share 
60%–80% sequence homology, gene expression levels of TfRs 
were analyzed along with LRPs. An increased expression of 
Lf receptors in the tissues from the NC-fed animals compared 
to control tissues gives a clue for possible internalization using 
these receptors. More importantly, higher LRP (Figures 6E 
and S5) and TfR (Figures 6F and S6) levels were detected 
in the intestine compared to control tissue or untreated cells, 
which suggest that when taken orally, intestinal uptake of these 
NCs occurs for further targeting the tumor site via the systemic 
circulation. The gene expressions of LRP and TfR isoforms 
MDA-MB-231 cells were also studied in order to compare the 
receptor-mediated internalization in vitro and in vivo.
Thus, based on the surface receptor–ligand chemistry, it 
could be possible that bLf could guide the NCs for enhanced 
internalization.
Analysis of blood and serum profile of mice
In a previously published study,7 we reported that 1.2% 
(w/w) diet of Fe-bLf raised the iron levels in serum from 
0.0053% to just 0.0069%, which was statistically insignifi-
cant (P0.05).8 The pharmacokinetic studies conducted in 
the same study8 showed that oral delivery of Fe-bLf ensured 
presence of Fe-bLf for 3 hours in serum postfeeding, and 
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Figure 5 histological analysis for cytotoxicity studies.
Notes: (A) Tissue pathology observation after the treatment is represented in the figure. Hematoxylin and eosin staining was carried out in order to observe the tissue 
integrity in the control and treatment groups. Five-micrometer-thin slices of intestine (Ts), kidney (ls), and brain (ls) from control (a, c, and e) and treated (b, d, f) mice 
were stained with hematoxylin and eosin was used as a counterstain. Observations were made under 100× oil immersion objective. (B) Immunohistochemical localization of 
acsc-Fe-blf Ncs using anti-lactoferrin antibody. Brain (ls), liver (ls), and intestine (Ts) sections from control (a, c, e) and treated (b, d, f) groups are shown.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; ls, longitudinal section; Ncs, nanocapsules/
nanocarriers; Ts, transverse section.
the levels of Fe-bLf were not detectable beyond 72 hours, 
thus ensuring clearance of protein from the body.
Our findings, shown in Table 2, are as follows. The 
hemoglobin level showed a 1.18-fold upsurge in mice 
treated with Fe-bLf and 1.26-fold increase in ACSC-Fe-bLf 
NC–treated mice when compared to untreated mice. The 
hematocrit levels were found to increase by 1.29-fold and 
1.49-fold in Fe-bLf and ACSC-Fe-bLf NCs, respectively. 
The iron concentration in both liver and spleen was increased 
in the treatment groups (1.11-, 1.18-fold and 1.06-, 1.090-
fold, respectively). The serum iron concentration was found 
to increase by 1.137-fold and 1.32-fold in both liver and 
spleen, respectively, and the serum calcium concentration 
was also found to be upregulated by 1.16- and 1.235-fold, 
respectively. Anemia, a common phenomenon as result of 
cancer treatment, is caused by bleeding, hemolysis, defi-
ciency of erythropoietic factors, gut infections, diarrhea, and 
other nutritional deficiencies.35,36 Long-term chemotherapy 
causes damage to the blood cells, in turn impairing eryth-
ropoiesis. In this paper we have shown clearly that Fe-bLf 
and Fe-bLf NCs significantly increase the serum iron levels, 
RBC count, hemoglobin count, etc. We have already shown 
that bLf and its iron-saturated forms have immunomodula-
tory properties and it leads to increase in iron, hemoglobin, 
and RBC count.8,37 Therefore, Fe-bLf can act as an alterna-
tive therapy for the patients undergoing chemotherapy as 
these patients are generally anemic.38
Conclusion
With current and predicted increase in breast cancer cases 
worldwide including Australia and side effects of the cyto-
toxic chemotherapy, it is becoming increasingly important for 
medical scientists to find safe, less toxic, and effective alter-
native therapies. In our previous publications, we reported 
that Fe-bLf in combination with lower doses of toxic antican-
cer chemotherapy was found to be more effective in various 
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Table 2 Serum iron, serum calcium, and blood hematological profile of control and experimental mice with bovine lactoferrin–fed 
groups and mice fed on control diet
Organ/cells Fe-bLf ACSC-Fe-bLf NCs Control diet
hemoglobin level (g/dl) 18.0±0.5* 19.2±2.5 15.2±1.5
hematocrit level (%) 65.5±5.5* 75.5±5.0 50.5±2.0
liver Fe (µg/g) 80±10* 85.6±10 72±15
spleen Fe (µg/g) 175±21* 180±14 165±10
rBcs (×106/mm3)a  8.5±2.5**  9.5±1.0  5.5±1.0
reticulocytes, ×109 cells/l 405±25* 450±20 349±15
reticulocyte hemoglobin content, pg 20±6** 24±5 12±4
serum iron (µg/g) 165±25** 192±12 145±20
serum calcium (mg/dl) 9.9±0.8* 10.5±2.0 8.5±1.8
Notes: aMean values of rBc counts were recorded in blood samples collected directly from the heart at the time of autopsy. Data are expressed as mean ± sD. **P0.001 
is the highly significant value from the control. *P0.05 is the significance value from the control.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; Ncs, nanocapsules/nanocarriers; rBc, red blood cell.
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Figure 6 expression of key receptors involved in the uptake of ceramic Ncs.
Notes: (A) Significant levels of increased iron in treatment groups (red bars) compared to control (blue) in case of spleen, liver, intestine, brain and tumor were observed. 
(B) lower left panel shows control group negative for Prussian blue staining. (C) Inset shows internalization of Fe-blf–loaded acsc Ncs near the cD31-stained area. (D) 
mirNa expression analysis from intestine, liver, spleen, and brain was carried out in Fe-blF-Nc–treated mice. (E) lrPI expression was comparatively higher in vitro when 
compared to in vivo. lrP2 mrNa levels were elevated in mice liver, brain, and intestine tissues. (F) expression of Tfr and its isoforms was high in MDa cells, liver, brain, and 
intestinal tissues. Data represent mean ± standard error of the mean. experiments were repeated three times independently with similar results. **P0.005; *P0.05.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; lrP, low-density lipoprotein receptor; mirNa, 
micro-rNa; Ncs, nanocapsules/nanocarriers; Tfr, transferrin receptor.
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 cancer types; however, recently, we found that Fe-bLf–loaded 
ACSC NCs alone showed more promising anticancer efficacy 
in both in vitro and in vivo studies (Figure 7). The NCs proved 
to be incredibly antitumorigenic based on the fact that none of 
the mice injected with breast cancer cells developed tumors 
in the xenograft models. Body condition scoring and tissue 
pathology designated safe and biocompatible nature of these 
NCs. Finally, novel new-generation–targeted natural and 
safe molecule–based nanomedicine and nanonutraceutical 
approaches could enhance further the antitumor efficacy to 
kill tumor cells sparing the normal body cells along with the 
lower doses of toxic chemotherapies.
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Figure S1 Time dependent internalization of Ncs.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; csc, chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; Ncs, 
nanocapsules/nanocarriers.
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Figure S2 Determining the percentage viability in MDa-MB2-31 cells with Nc 
treatments at 10 h.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; csc, 
chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; h, 
hours; Nc, nanocapsule/nanocarrier.
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Figure S3 Determining the percentage viability in MDa-MB2-31 cells with Nc 
treatments at 20 h.
Abbreviations: acsc, alginate-enclosed chitosan-coated calcium phosphate; 
csc, chitosan-coated calcium phosphate; h, hours; lf, lactoferrin; Nc, nanocapsule/
nanocarrier.
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Figure S4 Determining the clonogenic potential of MDa-MB-231 with Nc treatments.
Notes: (A) clonogenic potential of MDa-MB-231 was performed. (B) It was revealed that the CSC-Fe-bLf NCs led to a significant reduction (*P0.05) in 12 and 24 h and 
a highly significant reduction (**P0.005) in 48, 72, and 96 h.
Abbreviations: csc, chitosan-coated calcium phosphate; Fe-blf, iron-saturated bovine lactoferrin; h, hours; Ncs, nanocapsules/nanocarriers.
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Figure S5 agarose gel images of the Q-rT-Pcr (quantitative real time polymerase 
chain reaction) products.
Abbreviation: lrP, low-density lipoprotein receptor.
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Figure S6 agarose gel images of the Q-rT-Pcr (quantitative real time polymerase 
chain reaction) of Tfr and its isoforms.
Abbreviation: Tfr, transferrin receptor.
Table S1 comparison of physicochemical and biological characters in csc-Fe-blf Ncs and acsc-Fe-blf Ncs
Characteristics CSC-Fe-bLf NCs ACSC-Fe-bLf NCs
size, nm 205±15 322±27.2
Zeta potential -0.217 -1.29
Poly dispersity index 0.073 0.084
Encapsulating efficacy 80% –
loading capacity 25.8% –
Ic50 at 20 h, mg/ml 1.192 1.62 
Internalization efficacy (4×105 Ncs), % 86.6±2.25 43±1.5
Note: Data shown in the Size and Internalization efficacy row as mean ± SD.
Abbreviations: Ic50, half maximal inhibitory concentration; acsc, alginate-enclosed chitosan-coated calcium phosphate; csc , chitosan-coated calcium phosphate; Fe-blf, 
iron-saturated bovine lactoferrin; Ncs, nanocapsules/nanocarriers.
